An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)

ConditionsDilated Cardiomyopathy (DCM)BAG3 Mutation Associated Dilated Cardiomyopathy

Trial statusRecruiting

Trial phasePhase 1, Phase 2

Trial typeInterventional

Biological sexAll

Age18-55

SponsorAffinia Therapeutics

About this trial

This is a Phase 1/2, open-label, dose-exploration and dose-expansion, clinical trial evaluating the safety, tolerability, pharmacodynamics, and preliminary efficacy of a single intravenous infusion of AFTX-201 in adults with dilated cardiomyopathy caused by a BAG3 gene mutation

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

AFTX-201

Treatment groups

22 Participants

are divided into 1 treatment group

Sponsors and collaborators

Affinia Therapeutics

Lead sponsor

Source ClinicalTrials.gov